Background. Prostate cancer survivors with a rising prostate-specific antigen (PSA) level have few treatment options, experience a heightened state of uncertainty about their disease trajectory that might include the possibility of cancer metastasis and death, and often experience elevated levels of distress as they have to deal with a disease they thought they had conquered. Guided by self-regulation theory, the present study examined the cognitive and affective processes involved in shared decision making between physicians and patients who experience a rising PSA after definitive treatment for prostate cancer. Methods. In-depth interviews were conducted with 34 prostate cancer survivors who had been diagnosed with a rising PSA (i.e., biochemical failure) within the past 12 months. Survivors were asked about their experiences and affective responses after being diagnosed with a rising PSA and while weighing potential treatment options. In addition, patients were asked about their decision-making process for the initial prostate cancer treatment. Results.
Compared with the initial diagnosis, survivors with a rising PSA reported increased negative affect following their diagnosis, concern about the treatability of their disease, increased planning and health behavior change, heightened levels of worry preceding doctor appointments (especially prior to the discussion of PSA testing results), and a strong reliance on physicians' treatment recommendations. Conclusions. Prostate cancer survivors' decisionmaking processes for the treatment of a rising PSA are markedly different from those of the initial diagnosis of prostate cancer. Because patients experience heightened distress and rely more heavily on their physicians' recommendations with a rising PSA, interactions with the health care provider provide an excellent opportunity to address and assist patients with managing the uncertainty and distress inherent with rising PSA levels. Key words: prostate cancer; decision making; survivorship; androgen deprivation therapy; rising prostate specific antigen. (Med Decis Making 2015;35:477-486) D espite advances in prostate cancer treatment and favorable 5-year survival rates, an increasing number of prostate cancer survivors experience a rise in prostate-specific antigen (PSA) levels without evidence of widespread disease (e.g., metastases to other sites). A rising PSA refers to an elevated PSA level after initial prostate cancer treatment. 1 The widespread use of PSA testing for the detection of prostate cancer has resulted in a substantial shift in detection of the disease such that an increasing number of men are diagnosed and treated with clinically localized disease at a younger age 2,3 and eventually are more likely to experience a disease recurrence. It has been estimated that 40% of patients initially treated with surgery or radiation will eventually experience rising PSA levels, resulting in approximately 60,000 new cases per year. 4, 5 A rising PSA in this instance suggests recurrence of the cancer, although it might take months or even years to manifest clinically. During this time, most survivors are asymptomatic until bone metastases, which are associated with increased levels of pain, are detected through a scan.
Although multiple treatment options are available to survivors with a rising PSA, there is little agreement on a definitive or uniform approach to treatment as there are insufficient data to guide treatment recommendations. Existing data on the efficacy of various treatment options are sparse and derived primarily from single-institution studies or retrospectively analyzed data sets. 6 Most physicians recommend careful monitoring of PSA levels, especially in the early stages of a rising PSA. Intermittent or traditional hormone treatment is the most commonly chosen approach, although external-beam radiation and salvage prostatectomy are also available. The choice of one of these options is usually determined by clinical factors shown to influence progression from biochemical failure to metastatic disease. [7] [8] [9] These factors include PSA doubling time, PSA velocity, time of PSA recurrence, pathologic stage, Gleason score of the initial tumor at diagnosis, and presence of recurrent disease on biopsy after radiation treatment.
Given such clinical factors, patients and their physicians ideally evaluate available options and balance the potential benefits of treatment with possible side effects (e.g., for hormone treatment: loss of libido, hot flashes, loss of lean muscle mass, etc.) that negatively affect a patient's quality of life. The difficulty patients face in making a treatment decision is often compounded by inconsistent physician recommendations for patients with a rising PSA 10, 11 and by elevated levels of distress caused by the realization that the disease they thought they had conquered is returning, very likely leading to metastatic disease and eventually to death. 12 Thus, physicians and patients face a complex array of factors in deciding which treatment pathway, if any, to pursue. Although much research has examined treatment decision making among prostate cancer patients at initial diagnosis (e.g., Sylvester and others, 10 Moul, 11 and Sartor and others 12 ) , no prior studies have identified the decision-making processes at this later stage of the disease trajectory. [13] [14] [15] The goal of the present study was to examine these factors by qualitatively interviewing patients during the time of a rising PSA diagnosis.
Guided by self-regulation theory, 16, 17 our interview approach emphasized the importance of both cognitive and affective factors influencing information processing and decision making. Cognitive processes include patients' representations of prostate cancer, such as their perceptions and beliefs about the causes of the disease, its consequences on quality of everyday life, and its treatability. The simultaneously occurring affective distress arising from the uncertainties of the efficacy of treatment, its impact on quality of life, and its potential efficacy in extending life add an additional layer of factors affecting the decision-making process. 18 Because of the uncertainty and emotional distress surrounding a rising PSA diagnosis, it is possible that patients strongly rely on physicians' counsel and recommendations. The main objective of the present study was to engage patients in a detailed retrospective and comparative examination of the processes involved in making treatment decisions following their initial diagnosis of prostate cancer as well as the recent diagnosis of a rising PSA.
METHODS

Participants and Recruitment
Eligible participants for this study were prostate cancer survivors who were treated for early stage disease, had been diagnosed with biochemical failure within the past 12 months (indicating a possible recurrence), were not castrate resistant, and were able to provide informed consent and speak and understand English well enough to complete the interviews. Biochemical failure for surgical patients was defined as 2 consecutive PSA measurements of 0.2 ng/mL or higher after a nadir of less than 0.1 ng/ mL. 7, 19, 20 Failure for radiation patients was defined by criteria set by the ASTRO consensus panel (1997) of 3 consecutive elevations of the PSA level after a stable nadir, independent of baseline level. All survivors were recruited through their treating physicians (i.e., urologists or oncologists) at major medical centers in the New York metropolitan area between January 2011 and December 2011. After patients expressed interest and consented to the study, they completed a baseline questionnaire, which was distributed prior to their scheduled appointment. The institutional review boards (IRBs) of all participating institutions approved this study.
Procedures
The patients providing the current interview data were a simple random sample of participants from a longitudinal study involving data collection at 4 time points (3, 6, 9, and 12 months) following a diagnosis of a rising PSA. Patients were included regardless of the time and kind of treatments they had (e.g., surgery alone, or surgery followed by a course of radiation treatment) prior to the diagnosis of a rising PSA. Patients were personally interviewed at 2 possible study milestones: 1) once they made a treatment decision to address their rising PSA, or 2) at the end of the 12month study period if the patient continued to be monitored but no treatment decisions had been made. Interviews were conducted until thematic saturation occurred (i.e., no new themes or topics emerged).
Interviews
A random sample of 42 patients from the larger study sample (n = 125) were approached to participate in a follow-up phone interview. Of those approached, 34 patients participated, resulting in an 80% recruitment rate and a subsample that represented 27.2% of the entire study sample. Phone interviews averaged 25 to 30 minutes in length. Structured interview guides were developed based on our selfregulation theoretical framework, with an emphasis on cognitive and affective processes that have been shown to influence decision making. All interviews were conducted by a trained psychologist (M.D.).
Interviews were comprised of 3 main parts. The first part of the interview focused on patients' initial prostate cancer diagnosis and initial treatment decision. Patients were asked about the circumstances of their initial diagnosis, how they decided on their initial treatment (including the physician's role in discussing prognosis and decision making), experiences with treatment and potential side effects, and whether they experienced any continued urinary or sexual problems. Patients were also asked about their initial emotional reaction to the diagnosis.
The second part of the interview addressed patients' concerns about their rising PSA levels.
Patients were asked about their emotional state after they learned that their PSA levels were rising, whether they thought much about the rising PSA level, how they made sense of it (i.e., causes, consequences, where it comes from), what they thought could be done about their rising PSA, and what their priorities and goals were in dealing with the condition. When appropriate, patients were probed for negative emotions and experiences following their diagnoses.
The third part of the interview focused on patients' treatment options, especially hormone therapy (i.e., androgen deprivation therapy) and salvage radiation therapy. Patients were asked whether they knew when they would begin treatment, which factors prompted them to do something about their rising PSA (if they had), and how long it took them to make their decision (if they already made a decision). Patients were also asked what information and resources contributed to their decision making, including the physicians' role in decision making. Finally, patients were asked about the emotional impact of the new diagnosis of rising PSA. Because this ''watch and see'' approach of monitoring PSA levels is a valid treatment choice, all patients were asked the same questions regardless of whether they had made a decision to start active treatment. The interviewer concluded by thanking participants for their time and dedication to the study.
Data Analysis
All interviews were audio-recorded, transcribed by a professional transcription service, and validated by study investigators to ensure accurate and complete transcription. A theoretically derived preliminary coding sheet was developed to aid in the coding of answers. Two members of the study staff read all transcribed interviews and coded responses based on this coding sheet. New codes were added if both coders agreed on their necessity. Initial interrater reliability indicated moderate agreement between the 2 coders with a Cohen's kappa of 0.58 for the entire interview from the full sample. The coders then discussed and resolved their coding discrepancies and achieved perfect agreement (Cohen's kappa = 1.0).
RESULTS
Sample Characteristics
Pertinent patient demographics and clinical characteristics are summarized in Table 1 and the coded themes are summarized in Table 2 . A detailed description and discussion of themes follows.
Reactions to a Rising PSA Diagnosis: Negative Affect and Optimism
A majority of patients reported experiencing higher levels of negative affect when told their PSA was rising compared with the time when they were initially diagnosed with prostate cancer. Specifically, patients reported disappointment, discouragement, worry, and fear of death.
Well you know my first reaction was disappointed . . . obviously I go through a major surgery and then you find out that it worked to a point, but it was something that wasn't complete. So the first few months I wasn't really angry or depressed, I was disap- Although patients with a rising PSA reported feeling more worried, fearful, and disappointed than they did at initial diagnosis, they also reported being more grateful to be alive and expressed optimism about the future. The expressed optimism appears to help patients cope with their current situation and might counteract negative emotions that were present when they found out that their PSA started to rise. Whereas fighting the disease was often of utmost importance at the initial diagnosis, most patients expressed acceptance of their situation and being more aware about their potentially limited future. This translated into new plans for the foreseeable future: I'm spending more, traveling more, and donating more to charity at a faster pace than I might have otherwise. The changes among patients to engage in actively planning and being more accepting of their situation The Role of Follow-up Appointments: Promoting Worry
Although many patients reported being worried about their rising PSA levels and the possible recurrence of cancer, they did not report thinking about it on a daily basis. Rather, patients stated that they predominantly worried about their rising PSA levels only when prompted by a physician visit to get their PSA levels tested. Patients' positive feelings seemingly served as a buffer against stress and anxiety; however, worry returned when they were visiting their physician to check on their PSA levels. This is consistent with past research indicating that physician visits serve as ''worry promoters'' among cancer patients. 21 But at this point every time I go for a PSA test the week or 10 days before the test I notice that I'm becoming more tense, more irritable, more distracted, and until I hear the results I may stay that way This worry expressed prior to follow-up appointments that monitored rising PSA levels might prompt some patients to develop action plans. For instance, patients reported that being worried about their cancer's progression actually motivated them to live better lives and enjoy their lives more. Decision-making Processes: Monitoring PSA Levels and the Role of the Physician A distinct feature of being diagnosed with a rising PSA was that patients were not offered multiple treatment options. Rather, they had the choice between monitoring their PSA levels and deciding when to begin hormone therapy. Perhaps due to the unique features of decision making during this phase, most patients reported being concerned with tracking their PSA levels upon receiving a diagnosis of a rising PSA. They tracked and compared their own PSA levels to predesignated ''milestones,'' such as the time it took for a value to double or certain upper limits upon which treatment would be initiated. Patients' perceptions of such values were not necessarily medically accurate or based on physician recommendations (e.g., PSA .10). However, there is no gold standard cutoff PSA value to initiate hormone treatment; thus, patients adopted physicians' suggestions or invented their own ''rules'' on what is considered a cutoff for PSA levels. Well, I mean, it's in the back of my head if it gets to a certain point, they didn't give me a specific number, but I would assume if it went, like, 1 or 2 that would be quite an increase. [Patient 220] So it [PSA level] is going to somewhere around 9 or 10, when it gets to that point, we will probably do the hormone therapy. [ Patient 20] Perhaps due to the unique nature of the limited number of options with rising PSA versus initial diagnosis as well as the developed relationship with their treating physician, patients relied much more heavily on their physicians' recommendations in making a treatment decision upon receiving a diagnosis of a rising PSA. At initial diagnosis, many patients described themselves as having an independent and active voice in treatment decisions. They also reported seeking second opinions. In contrast, patients reported relying on their physicians' advice more after they had been diagnosed with a rising PSA than they did at initial diagnosis. In fact, more patients with a rising PSA made their treatment decision based solely on their physicians' preferences or advice than at initial diagnosis. 
DISCUSSION
The present study provides new insight into decision-making processes that occur among prostate cancer survivors with rising PSA levels, an increasingly large segment of cancer survivors. 4, 5 As expected and in accord with self-regulation theory, 16, 17 the data suggest that both patient-based cognitive and affective processes and interpersonal processes (i.e., the physician-patient relationship) shape the decision-making processes. Specifically, results indicated the 3 most distinct features of the decision-making processes upon diagnosis of a rising PSA are that: 1) patients experience an increase in negative affect and worry and are also more skeptical of the curability of their disease, 2) follow-up appointments during which patients' PSA levels are monitored are triggers for increasing worry and anxiety surrounding their prognosis, and 3) patients rely heavily on their physicians during the decisionmaking process. These 3 main findings suggest that physicians ought to be attuned to patients' increased emotional vulnerability upon receiving this diagnosis; be aware that follow-up appointments, even though considered routine, will likely exacerbate distress; and know that they play a crucial role in recommending treatment options and guiding patients through the treatment decision-making process. These results are discussed in detail below within a cognitive and affective processes framework.
Cognitive Processes
As expected, patients with a rising PSA level were more skeptical of their treatment being curative than they were at initial diagnosis. 13 The shift in the perception of many prostate cancer patients from believing that their cancer was curable following the initial treatment to realizing that the cancer had returned following a diagnosis of rising PSA was associated with a marked change in the perception of control over their cancer. 22 This change in illness perception was associated with changes in patients' action plans, such as changes in everyday behavior including increased spending and saving less money, and attempts to enjoy life more. These are all indications of the assumption that life will be shorter than previously expected.
In addition to reporting they were no longer cured, patients also reported that they closely monitored their PSA levels and compared them with a ''cutoff'' or doubling rate. These values, however, were not always medically accurate. This suggests that physicians may want to provide medically accurate targets to patients, even in the absence of gold standards, in order to increase their understanding of the disease and its time trajectory. Additionally, although gold standards for PSA levels do not exist, most urologists would provide androgen deprivation therapy for a rising PSA, especially if the PSA is rapidly increasing. Prior treatment, however, may factor into which options are available to patients (e.g., radiation patients are unlikely to have further radiation). As such, physicians should incorporate these concerns into treatment option discussions with patients.
Affective Processes
Patients also reported feeling disappointed, discouraged, or fearful upon being diagnosed with a rising PSA level. Despite this increase in negative affect, patients with rising PSA levels also reported being hopeful, optimistic, and happy to be alive. The presence of positive affect is an indication of acceptance of the situation and the desire to enjoy life despite the specter of a worsening disease. In short, patients did not seem to let worry and distress influence their day-to-day activities. Rather, patients reported feeling worried predominately prior to check-up visits where they would receive results of their PSA tests, a finding previously reported for breast cancer survivors. 21 Heightened affective processes are likely to influence disease and treatment-relevant information processing and by extension treatment decision making through compromised processing and integration of information. 23 Supporting this conclusion, prostate cancer patients have listed emotions as more reliable and valuable in treatment decisions than riskbased information. 24 
Physician-Patient Relational Processes
Perhaps the most unique finding from the present study is that patients relied more heavily on their physicians' recommendations when making treatment decisions for a rising PSA than they did at initial diagnosis. Whereas many patients at initial diagnosis get second opinions 25 and reported doing so in the present study, some patients with rising PSA levels reported relying solely on their physicians' advice in making treatment decisions. In the present study, patient-physician relationships ranged from patients having known their current physician for up to 18 years to being referred to the physician upon receiving a diagnosis of a rising PSA. Despite the length of the relationship, many patients reported full reliance on their physicians' opinions and recommendations, underscoring the important role that physicians play in decision making in this situation.
The present study does not provide sufficient data to fully explain this shift in decision-making behavior. However, patients indicated that relying on their physicians' recommendations reduced the amount of burden they felt in making a decision about treatment. It is certainly possible that some patients, after having dealt with the disease for a number of years, felt ready to turn over ''responsibility'' for their disease to their physician, effectively experiencing decision fatigue. Moreover, patients may have relied more on their physicians' recommendations because the treatment options were less varied than they were at initial diagnosis or because they viewed the physicians' recommendations (to go on hormone therapy or keep monitoring PSA levels) as less severe than other options such as surgery. Future research should examine why there is a major shift in how much patients rely on their physicians' recommendations when diagnosed with a rising PSA versus initial diagnosis.
These findings are in line with previous research which indicates that both the experience and stage of illness influence the degree to which patients desire to be involved in decision making surrounding their care. 26 For instance, past research indicates that cancer patients whose condition had recently worsened were more likely to desire less involvement in decision making than those whose condition remained unchanged. 27 Similarly, the present study found that once patients' conditions had progressed with a rising PSA, they more frequently reported relying on physicians to aid in decision making. Health status has also been shown to influence patients' desire for information. Several studies have shown that patients with severe illness may prefer to be less involved in decision making than patients with minor illnesses. 26 As such, patients who face a more progressive and possibly more severe diagnosis than they did initially may desire less involvement in their treatment decision making.
Limitations and Directions for Future Research
The present study provides novel insight into the treatment decision-making processes of prostate cancer survivors diagnosed with rising PSA levels; however, it does have some limitations that must be considered in interpreting the results. One limitation is the retrospective description of patients' treatment decision-making processes at initial diagnosis. Given that the average amount of time since initial diagnosis among this sample was approximately 9 years, it is possible that patients misremembered the cognitive, affective, or physician-patient relational processes that originally guided their treatment decision making. However, retrospective accounts of prostate cancer treatment decision making have been a common form of inquiry. 14 The added advantage of asking patients to retrospectively recall their decision making is that it allows for a comparison of the same patient's treatment decision making for a rising PSA rather than comparing 2 distinct groups to one another. Because emotional reactions attenuate over time, leading to errors in recall of emotional experiences, 28 it is possible that the more recent emotional reactions to rising PSA levels may be reported as higher than those associated with the initial diagnosis simply because less time has passed.
Another limitation of the present study is that the data are qualitative and thus cannot be used to formally test hypotheses. Although qualitative data allow for exploration of themes and are hypothesis generating, it should be noted that the present sample was not representative of the majority of prostate cancer patients, which limits the generalizability of the data. Rather, the results from the present study provide a framework in which to continue developing and ultimately testing hypotheses using quantitative methods.
Another limiting factor of this study is that we did not fully probe all individuals for negative themes. For instance, some patients were probed about potential worry or uncertainty more deeply, when appropriate, but not all patients were asked about these potential concerns to the same extent.
Additionally, this study has limited generalizability given that the sample consisted of predominately white, well-educated men. Patient populations with lower levels of education may also exhibit lower levels of health literacy that, in turn, influence information processing and decision making. Future research should examine more racially and ethnically diverse samples as well as samples of individuals with lower levels of education to determine how these variables influence the decision-making processes of prostate cancer survivors with rising PSA levels.
Finally, another limitation of the present study is that the decision-making and physician-patient relational processes examined in this study were only explored from the patient point of view. Examining these processes from the physician's standpoint would add another layer of information that would be crucial in informing future intervention development. By examining the physicians' attitudes and beliefs surrounding this situation, future research could create more targeted interventions to improve communication and shared decision making among patients and physicians.
Practice Implications
In short, patients' reactions and decision making upon receiving a rising PSA diagnosis differed from those at the initial diagnosis across 3 broad themes. First, patients are likely to experience strong negative affect and are more skeptical about the treatability of their disease. Even if such feelings are not communicated to the consulting physician, health care providers need to be aware that patients are more emotionally vulnerable and potentially in need of support. A systematic review of physician-patient communication demonstrated that physicians' abilities to communicate well with patients positively affected a multitude of patient outcomes, including emotional well-being, physical symptoms, and physiological measures. 29 Thus, a physician's ability to communicate empathically (e.g., acknowledging, praising, reassuring, encouraging 30 ) with patients during this time will improve patients' emotional and physical well-being and by extension improve information processing and decision making.
Second, follow-up appointments that are designed to monitor patients' PSA levels often lead to high levels of worry and anxiety about the potential progression of their disease. Health care providers should be sensitive to the signs of distress and the psychosocial needs of their patients at this point in the disease trajectory. Physicians' appointments with patients diagnosed with a rising PSA provide an opportunity to respond to these psychological needs. PSA levels have been cited as a source of great uncertainty (and thus added worry and distress) for prostate cancer patients. 31 Thus, patients might benefit from physicians providing a trajectory of how long to watch their PSA levels as well as giving them more certainty and information regarding criteria for taking action once reaching a certain PSA level. These trajectories could be based on PSA doubling rates that have been shown to be effective in monitoring disease progression. 32 Although providing guidelines might be helpful, focusing on addressing uncertainty and how to make decisions under uncertainty might be most helpful to patients with rising PSA levels.
Finally, patients rely heavily on their physicians for making decisions. This gives the health care provider a unique opportunity to introduce programs to support patients' decision-making processes as well as emotional well-being. Specifically, physicians' providing additional information could help reduce the burden of decision making that patients often face at this later point of their disease.
CONCLUSION
This study illustrates that decision-making processes vary depending on the time and nature of patients' prostate cancer diagnoses. The present results highlight which components of the decisionmaking process are distinctly different for prostate cancer survivors diagnosed with a rising PSA compared with those at the time of initial cancer diagnosis. Given the differences in decision-making processes, it is important for physicians and other medical staff to be aware of the specific needs of patients at each stage. Understanding the increased role of importance that physicians play among prostate cancer survivors with rising PSA levels as well as the increased distress experienced by patients during follow-up appointments could allow for better patient care, physician-patient communication, and support of needs. Ultimately, addressing the added distress from uncertainty surrounding rising PSA levels might improve patients' outcomes, including quality of life and satisfaction with care.
